Ondine Biomedical Inc. Share Chat - Chat About OBI Shares - OBI | Page 28
ADVFN Logo ADVFN

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

OBI Ondine Biomedical Inc.

7.60
-0.15 (-1.94%)
13 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Ondine Biomedical Inc. LSE:OBI London Ordinary Share CA68234M2058 COM SHS NPV (CDI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.15 -1.94% 7.60 7.50 8.00 7.75 7.55 7.75 6,708 16:35:21
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Biological Pds,ex Diagnstics 1.2M -14.41M -0.0357 -2.17 31.31M
Ondine Biomedical Inc. is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker OBI. The last closing price for Ondine Biomedical was 7.75p. Over the last year, Ondine Biomedical shares have traded in a share price range of 4.50p to 11.00p.

Ondine Biomedical currently has 404,004,731 shares in issue. The market capitalisation of Ondine Biomedical is £31.31 million. Ondine Biomedical has a price to earnings ratio (PE ratio) of -2.17.

Ondine Biomedical Share Discussion Threads

Showing 676 to 697 of 1300 messages
Chat Pages: Latest  28  27  26  25  24  23  22  21  20  19  18  17  Older
DateSubjectAuthorDiscuss
06/3/2024
08:54
purple if was jam today then we'll be all millionaires !
z1co
05/3/2024
19:46
Re, "Gets sold into albeit small volume and it still falls

Why ? Market does not see any meaningful revenues soon"

=====================================

There is effectively no 'market' as such for these shares. It's really hard to find a platform that offer them. I had to go to AJBell to get mine, as Halifax wouldn't sell them. Even on AJB there is often no quote to buy or sell. Further more, it's often impossible to place a buy or sell order.

This share is symbolic of the failure of the UK market to take pre-profit tech shares seriously.

=====================================

Ondine starts first UK health economics study

The York Health Economic Consortium will undertake the first UK health economic analysis of Ondine's Steriwave light-activated antimicrobial to reduce Surgical Site Infections

Ondine Biomedical Inc. (LON:OBI), Mid Yorkshire Teaching NHS Trust, and Health Innovation Yorkshire and Humber are partnering with the York Health Economics Consortium (YHEC) to evaluate the use of Ondine's light-activated antimicrobial, Steriwave®, to reduce the incidence of surgical site infections (SSIs).

SSIs are one of the most common healthcare-associated infections (HAIs) and affect one in every 20 patients who undergo a surgical procedure in the NHS. SSIs can cost up to £100,000 per patient, and the overall cost of HAIs to NHS England is over £2 billion a year. These costs are expected to rise as growing rates of antimicrobial resistance (AMR) make the current standard of care - the antibiotic mupirocin - less effective.



Steriwave uses a proprietary photosensitizer, which is activated by a specific wavelength of red light, to eliminate infection-causing pathogens in the nose. The nose is a reservoir for pathogens like Staphylococcus aureus and MRSA which are known to cause SSIs. Steriwave eliminates these pathogens, including superbugs, in a painless five-minute treatment and prevents them from spreading and causing infections. Importantly, unlike today's antibiotics, the use of Steriwave does not trigger antimicrobial resistance.


The health economic analysis is being undertaken by YHEC, an internationally renowned provider of health economics evaluations, and will supplement the ongoing Steriwave pilot at Mid Yorkshire Teaching NHS Trust, which involves 500 elective hip and knee surgery patients over a period of six months. The findings will be used to support adoption of Steriwave across the NHS.

Dr Stuart Bond, Consultant Antimicrobial Pharmacist and Director of Innovation at Mid Yorkshire Teaching NHS Trust, commented: "We are very pleased to be partnering with Ondine and the YHEC on this economic analysis to support the promising results of the Steriwave pilot we have seen so far. The data from the health economic analysis will support the results of our pilot, and we hope to be able to share these later this year."

Helen Hoyland, Head of Health Innovation Yorkshire & Humber's Office of Life Sciences portfolio, said: "Health Innovation Yorkshire and Humber (formerly the Academic Health Science Network for the region) is pleased to be supporting this evaluation. We are commissioned by the Office of Life Sciences to support real-world evidence generation. We will work with the innovators and the Trust to publish the evaluation data, and then subsequently look to support further opportunities for the spread and adoption of Steriwave, working alongside the West Yorkshire Innovation Hub".

Steriwave is also being used in major hospitals across Canada, including Vancouver General Hospital (VGH), The Ottawa Hospital (TOH), and the Mazankowski Alberta Heart Institute. Research recently published by VGH in the Canadian Journal of Surgery showed that the use of Steriwave in patients undergoing spine surgery resulted in a 66.5% reduction in post-surgical infection rates and $2.5 million in annual savings.[i] No serious adverse events have ever been reported from Steriwave treatment.

bamboo2
05/3/2024
18:22
Finally some news

Ondine starts first UK health economics study

The York Health Economic Consortium will undertake the first UK health economic analysis of Ondine's Steriwave light-activated antimicrobial to reduce Surgical Site Infections

Ondine Biomedical Inc. (LON:OBI), Mid Yorkshire Teaching NHS Trust, and Health Innovation Yorkshire and Humber are partnering with the York Health Economics Consortium (YHEC) to evaluate the use of Ondine's light-activated antimicrobial, Steriwave®, to reduce the incidence of surgical site infections (SSIs).

SSIs are one of the most common healthcare-associated infections (HAIs) and affect one in every 20 patients who undergo a surgical procedure in the NHS. SSIs can cost up to £100,000 per patient, and the overall cost of HAIs to NHS England is over £2 billion a year. These costs are expected to rise as growing rates of antimicrobial resistance (AMR) make the current standard of care - the antibiotic mupirocin - less effective.



Steriwave uses a proprietary photosensitizer, which is activated by a specific wavelength of red light, to eliminate infection-causing pathogens in the nose. The nose is a reservoir for pathogens like Staphylococcus aureus and MRSA which are known to cause SSIs. Steriwave eliminates these pathogens, including superbugs, in a painless five-minute treatment and prevents them from spreading and causing infections. Importantly, unlike today's antibiotics, the use of Steriwave does not trigger antimicrobial resistance.


The health economic analysis is being undertaken by YHEC, an internationally renowned provider of health economics evaluations, and will supplement the ongoing Steriwave pilot at Mid Yorkshire Teaching NHS Trust, which involves 500 elective hip and knee surgery patients over a period of six months. The findings will be used to support adoption of Steriwave across the NHS.

Dr Stuart Bond, Consultant Antimicrobial Pharmacist and Director of Innovation at Mid Yorkshire Teaching NHS Trust, commented: "We are very pleased to be partnering with Ondine and the YHEC on this economic analysis to support the promising results of the Steriwave pilot we have seen so far. The data from the health economic analysis will support the results of our pilot, and we hope to be able to share these later this year."

Helen Hoyland, Head of Health Innovation Yorkshire & Humber's Office of Life Sciences portfolio, said: "Health Innovation Yorkshire and Humber (formerly the Academic Health Science Network for the region) is pleased to be supporting this evaluation. We are commissioned by the Office of Life Sciences to support real-world evidence generation. We will work with the innovators and the Trust to publish the evaluation data, and then subsequently look to support further opportunities for the spread and adoption of Steriwave, working alongside the West Yorkshire Innovation Hub".

Steriwave is also being used in major hospitals across Canada, including Vancouver General Hospital (VGH), The Ottawa Hospital (TOH), and the Mazankowski Alberta Heart Institute. Research recently published by VGH in the Canadian Journal of Surgery showed that the use of Steriwave in patients undergoing spine surgery resulted in a 66.5% reduction in post-surgical infection rates and $2.5 million in annual savings.[i] No serious adverse events have ever been reported from Steriwave treatment.

z1co
05/3/2024
16:27
Trial in Canada , will know conclusion at the end of 2024

hxxps://www.saltwire.com/atlantic-canada/more/reducing-surgical-site-infections-through-technology-100938586/

jailbird
05/3/2024
16:17
The Global Mupirocin Market

hxxps://www.cognitivemarketresearch.com/mupirocin-market-report

Good info here, gives an idea where Steriwave can challenge

jailbird
05/3/2024
16:13
https://reports.valuates.com/market-reports/QYRE-Auto-30N15919/global-and-india-mupirocin-ointmentHuge market in India for the mupirocin ointment.Is OBI have an ointment product India market would be huge for OBIShould be going for this as well
jailbird
05/3/2024
13:46
More news on evaluation pilots Gets sold into albeit small volume and it still falls .Why ? Market does not see any meaningful revenues soon This time next year , should be the year if all goes well for take up
jailbird
04/3/2024
12:54
In Q2 2024 now and the company is very quiet Still trying to figure their margins per patient.When will we see meaningful revenues and profits ?
jailbird
26/2/2024
12:41
seems like the 5k seller split his 20k shares into 4 trades t which has knocked the bid slightly. . currently being offered 9.65 for 50k so its liquid.

in this market its not suprising its gone negative when it finally showed its hand.

damn market is the worse ive ever seen it in 15 years.

hopefully good news comes soon and we can kick back up to the 12p area gl

purple11
16/2/2024
15:31
Saved the hospital approx $2.25m a year Doing some more research , old news but new to me In 2011 an eight-year study conducted by the hospital was published in the Canadian Journal of Surgery. The research involved 13,493 patients with 8823 patients receiving Steriwave.The paper concludes that nasal photodisinfection should be the standard of care for all patients undergoing emergent or elective spine surgeries.It showed a 66.5 per cent reduction in surgical site infections (SSIs) following spine surgery when Ondine's Steriwave nasal photodisinfection was implemented in the universal pre-surgical infection prevention protocol. The study also found that the hospital saved $19.9 million net over the study period (2011 to 2019).
jailbird
01/2/2024
18:07
so easy and convenient only a nasal spray
purple11
31/1/2024
15:31
Yes. it would be an interesting number if OBI were able to supply it. Perhaps the volumes are not significant enough to publish as yet.
marvelman
31/1/2024
14:49
Trouble finding the exact info I was looking for but found this page 49 of conclusion Lists the countries it is available Unsure if all are either OTC or in hospitals or both , depends on the product I guess https://archive.hshsl.umaryland.edu/bitstream/handle/10713/17685/Mupirocin_final.pdf?sequence=1
jailbird
31/1/2024
14:32
Hi MMThe other thing I am going to look at is use of Mupricon outside the USA, specifically countries where Steriwave have received approvals . This is good way to gauge to see if Steriwave is taking market share from Mupirocin in these countries We cannot compare within the USA as Steriwave needs to be FDA approved first Back to Google
jailbird
31/1/2024
13:50
A balanced post Jailbird. From my own research as a non medic is that Steriwave is virtually a full replacement for Mupirocin but much faster to implement in practice although I am sure this discussion has been done before by those far more knowledgeable than myself.
marvelman
31/1/2024
08:42
Very positive so far , small steps Reading up on this field more Obviously Mupirocin is the main competitor here . But to me it appears Steriwave is just as good if not better but I am not sure if the are effective against the same bacteria or others too , does anyone know from top of their head?Mupirocin is still preferred it seems from recent article , so Steriwave needs to continue to prove it is the better option both as an effective treatment and cost wise too to compete and replace MupirocinNot sure if both have a place in the market The big boys have financial clout to beat if competitors that threaten their dominance Something to consider I guess in some cases this is why competitors get bought out https://www.ucihealth.org/news/2023/10/swap-out-clinical-trial
jailbird
31/1/2024
08:26
Microbiome research supports use of Steriwave

Ondine Biomedical demonstrated that photodisinfection does not harm the nasal microbiome

Research presented by Canadian life sciences company, Ondine Biomedical Inc. (LON:OBI), at the prestigious SPIE Photonics West conference in San Francisco, California shows that treatment with its Steriwave® Nasal Photodisinfection System significantly reduces pathogens in the nose - a reservoir for bacteria - yet does not produce long-term adverse effects on the nasal microbiome.[*]

Upon analysis of nasal swab samples, the research demonstrated an immediate and highly significant (99.9+% ~3 log10) reduction in viable bacterial cells and number of species, sustained for at least 24 hours. Importantly, within a week, the microbiome rebounded to its original diversity and quantity. These findings support Steriwave as an efficient, potent, short-acting, and non-selective method of nasal decolonization, with the advantage of rapid recovery of the native microbiome post-treatment.

In comparison to antibiotics, the study demonstrated that Steriwave is far less likely to significantly alter the native microbiota. The antibiotic mupirocin, commonly used for nasal decolonization, has been shown to affect microbiota diversity for over 6 months, allowing disease-causing pathogens like Staphylococcus aureus to colonize the nose before beneficial species, putting patients at increased risk of infection.[1] Steriwave, in contrast, offers a more favourable profile with the study results showing a reduced risk of long-term microbiome disruption, as the microbiome consistently returns to baseline.

Notably, minimizing microbiome disruption is also important in safeguarding immune function, reducing vulnerability to infectious diseases by maintenance of a microecological environment populated by beneficial commensal microbes instead of disease-causing species.[2] The oral research presentation, delivered by Ondine's Director of Research and Development, Dr. Caetano Sabino, reported results from an exploratory study involving 35 healthy volunteers, examining the responses of the nasal microbial population after Steriwave treatment.

Organized by SPIE, the international society for optics and photonics, SPIE Photonics West is the largest annual event for optic and photonic technologies and one of the world's largest scientific conferences. Ondine's oral presentation, titled "Microbiome Analysis of Photodynamic Nasal Decolonization," was delivered at 10:20am on Tuesday 30 January, as part of the "Photonic Diagnosis, Monitoring, Prevention, and Treatment of Infections and Inflammatory Diseases" session.

bamboo2
26/1/2024
07:43
This has got to be the best rns I can find this morning, and I am already invested in this.
luckyabbeygale
26/1/2024
07:28
ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine", or the "Company")

Ondine unveils new research at SPIE Photonics West

Canadian life sciences company Ondine Biomedical Inc. (LON: OBI) will present new research at the SPIE Photonics West conference in San Francisco, California. The presentation will provide details of an exploratory study showing that photodisinfection significantly reduces pathogens in the nose - a reservoir for bacteria - yet does not produce long-term adverse effects on the nasal microbiome.1 Organised by SPIE, the international society for optics and photonics, SPIE Photonics West is the largest annual event for optic and photonic technologies and one of the largest scientific conferences in the world.

These results demonstrate that Steriwave is an effective, potent, short-acting, and non-selective method of nasal decolonization, while permitting rapid recovery of the native microbiome at one week after treatment. The study involved analyzing nasal swabs from 35 healthy volunteers after being treated with Ondine's Steriwave® Nasal Photodisinfection System.

The oral presentation will be delivered by Ondine's Director of Research and Development, Dr Caetano Sabino, at 9am on Tuesday, 30 January 2024, as part of the "Photonic Diagnosis, Monitoring, Prevention, and Treatment of Infections and Inflammatory Diseases" session.

The "Microbiome Analysis of Photodynamic Nasal Decolonization" abstract can be accessed here.

_________

1 The nasal microbiome consists of a complex community of microorganisms - fungi, parasites, viruses, and bacteria - that can act in a symbiotic relationship in the nasal cavity.

z1co
24/1/2024
15:58
CHOO CHOO!
purple11
24/1/2024
15:11
No, just on my watchlist for now Expect 9p to be the bottom now unless they have to dilute again
jailbird
24/1/2024
15:04
Not really about balance sheet birdie
Its forward looking just like the tech over in the states billion market cap no.income at all .

Let's see what transpires with the big CFO

You hold shares or not??

senn1
Chat Pages: Latest  28  27  26  25  24  23  22  21  20  19  18  17  Older

Your Recent History

Delayed Upgrade Clock